Lifecore (LFCR) Biomedical announced that it has appointed Mark DaFonseca as chief commercial officer. A seasoned CDMO and pharmaceutical services executive, DaFonseca has nearly 30 years of pharmaceutical industry experience spanning all aspects of drug development from preclinical and chemistry, manufacturing and controls activities through late-stage clinical trials.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LFCR:
- UnitedHealth downgraded, Home Depot upgraded: Wall Street’s top analyst calls
- Lifecore initiated with an Outperform at William Blair
- Lifecore Biomedical’s Promising Growth Trajectory: Buy Rating with 34% Upside Potential
- Lifecore appoints Salus as chief legal, administration officer
- Lifecore pullback creates attractive entry point, says Craig-Hallum